A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma
Sponsor: MedImmune LLC
Terminated
Study is replaced by MI-CP198 per CPM.
Other terminated trials from MedImmune LLC
- TNBC - Triple-Negative Breast Cancer · Phase PHASE1 · May 2023
- Healthy Volunteers · Phase PHASE1 · May 2020
- Colorectal Neoplasms · Phase PHASE1 · Oct 2018
- CTCL · Phase PHASE1 · Oct 2018
- Respiratory Syncytial Virus · Phase PHASE2 · Nov 2016
More terminations from MedImmune LLC
Listed as NCT00483041, this PHASE2 trial focuses on Asthma and remains terminated or withdrawn. Sponsored by MedImmune LLC, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedImmune LLC
For direct contact, visit the study record on ClinicalTrials.gov .